ALLERGY IMMUNOTHERAPY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global allergy immunotherapy market is estimated to be valued at USD 2,740.6 Mn in 2025, and is expected to exhibit a CAGR of 9.8% during the forecast period (2025-2032). Allergy immunotherapy, commonly known as allergy shots or desensitization injections, refer to a medical treatment for certain allergies. It involves exposing people to gradually increasing amounts of allergen(s), with goal of decreasing the symptoms caused by the allergic response. The therapy is strictly administered under a physician's supervision. By administering controlled amounts of allergens, immunotherapy can lead to reduction in symptoms over time. It aims to reduce sensitivity to the identified allergens and lessen the patient's need for medication. The treatment usually spans 3-5 years depending on the individual's response and may provide long lasting relief from symptoms upon completion of therapy.

Market Dynamics

Global allergy immunotherapy market growth is primarily driven by rising prevalence of allergic diseases globally. Allergic rhinitis and asthma are among the most common observed chronic health issues. Growing environmental pollution and changing lifestyle factors have contributed to the allergy epidemic. Stringent regulatory guidelines for accurate diagnosis and management of allergic disorders further aid early adoption of immunotherapy. Development of sublingual and subcutaneous allergy vaccines with improved tolerability and faster onset of action can provide opportunities for the market growth. Adoption of recombinant antigen technologies and customized allergen extracts tailored to individual patients are key trends spurring R&D initiatives. However, high costs associated with prolonged therapy and lack of awareness in developing nations can hamper the market growth.

Key Features of the Study

• This report provides an in-depth analysis of the global allergy immunotherapy market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global allergy immunotherapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Stallergenes Greer, ALK-Abello A/S, Allergy Therapeutics, Allergopharma, HAL Allergy Group, Aimmune Therapeutics, DBV Technologies, Leti Pharma, Jubilant HollisterStier, Merck KGaA, Biomay AG, Hollister Allergy, Aravax Pty Ltd, Allovate, LLC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global allergy immunotherapy market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global allergy immunotherapy market.

Market Segmentation

• Treatment Type Insights (Revenue, USD Mn, 2020 - 2032)
• Subcutaneous Immunotherapy (SCIT)
• Sublingual Immunotherapy (SLIT)
• 10-30 MeV
• 30 -70 MeV
• Allergy Type Insights (Revenue, USD Mn, 2020 - 2032)
• Allergic Rhinitis
• Allergic Asthma
• Food Allergy
• Venom Allergy
• Others
• Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Stallergenes Greer
• ALK-Abello A/S
• Allergy Therapeutics
• Allergopharma
• HAL Allergy Group
• Aimmune Therapeutics
• DBV Technologies
• Leti Pharma
• Jubilant HollisterStier
• Merck KGaA
• Biomay AG
• Hollister Allergy
• Aravax Pty Ltd.
• Allovate, LLC